Kolon Life Science Inc.

KOSDAQ:A102940 Stock Report

Market Cap: ₩291.3b

Kolon Life Science Past Earnings Performance

Past criteria checks 0/6

Kolon Life Science's earnings have been declining at an average annual rate of -0.4%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been declining at an average rate of 0.4% per year.

Key information

-0.4%

Earnings growth rate

0.2%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate-0.4%
Return on equity-79.4%
Net Margin-60.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

There's Reason For Concern Over Kolon Life Science Inc.'s (KOSDAQ:102940) Massive 45% Price Jump

Dec 13
There's Reason For Concern Over Kolon Life Science Inc.'s (KOSDAQ:102940) Massive 45% Price Jump

Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%

Mar 02
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%

We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt

Mar 12
We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt

A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns

Jan 18
A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns

Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt

Nov 26
Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt

Revenue & Expenses Breakdown

How Kolon Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A102940 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24147,977-89,71319,24716,486
30 Jun 24140,273-84,23419,53916,207
31 Mar 24131,823-30,72419,91514,982
31 Dec 23124,639-33,59920,22714,892
30 Sep 23130,353-19,77420,03913,542
30 Jun 23141,227-11,86919,98712,914
31 Mar 23164,138-85919,94214,206
31 Dec 22161,5844,01619,58113,583
30 Sep 22166,885-4,82817,19614,707
30 Jun 22167,707-4,94017,13614,653
31 Mar 22155,075-3,69317,17013,550
31 Dec 21165,485-1,37517,32014,327
30 Sep 21135,045-31,62720,06213,804
30 Jun 21134,850-29,15421,73914,032
31 Mar 21131,508-40,48525,03013,634
31 Dec 20129,413-43,19527,88813,154
31 Dec 19148,541-92,32330,45218,490

Quality Earnings: A102940 is currently unprofitable.

Growing Profit Margin: A102940 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A102940 is unprofitable, and losses have increased over the past 5 years at a rate of 0.4% per year.

Accelerating Growth: Unable to compare A102940's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A102940 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22.3%).

Return on Equity

High ROE: A102940 has a negative Return on Equity (-79.36%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:32
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kolon Life Science Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
JooYong KimBookook Securities Co. Ltd
Bora ChungDaishin Securities Co. Ltd.
Ha Young KangDAOL Investment & Securities Co., Ltd.